Stay updated with breaking news from Acelyrin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Acelyrin (NASDAQ:SLRN – Free Report) had its price objective reduced by Morgan Stanley from $19.00 to $13.00 in a research note published on Wednesday morning, Benzinga reports. They currently have an equal weight rating on the stock. Several other analysts also recently weighed in on SLRN. Jefferies Financial Group reduced their price objective on shares […]
HC Wainwright restated their buy rating on shares of Acelyrin (NASDAQ:SLRN – Free Report) in a research report sent to investors on Tuesday morning, Benzinga reports. HC Wainwright currently has a $30.00 price objective on the stock. Separately, Morgan Stanley lowered Acelyrin from an overweight rating to an equal weight rating and lowered their price […]
By Chris Wack Fortrea said in a filing to the U.S. Securities and Exchange Commission that it disputes the accuracy of statements made by Acelyrin regarding...
HC Wainwright reaffirmed their buy rating on shares of Acelyrin (NASDAQ:SLRN – Free Report) in a research note issued to investors on Tuesday, Benzinga reports. HC Wainwright currently has a $30.00 price target on the stock. Separately, Morgan Stanley cut Acelyrin from an overweight rating to an equal weight rating and dropped their target price […]
NEW YORK, Nov. 27, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ACELYRIN, INC....